The experience with the application of first-line chemotherapy regimen with EDP-M (etoposide + doxorubicin + cisplatin + mitotane) in patients with advanced adrenocortical carcinoma in the Russian Federation
- Authors: Kolomeytseva AA1, Yemelyanova GS2, Gorbunova VA1, Orel NF1, Perevodchikova NI1, Bokhyan VY.1, Fedenko AA1
-
Affiliations:
- N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
- A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation
- Issue: Vol 19, No 3 (2017)
- Pages: 42-45
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/27146
- ID: 27146
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
A A Kolomeytseva
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: almed2002@mail.ru
канд. мед. наук, ст. науч. сотр. отд-ния химиотерапии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
G S Yemelyanova
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation
Email: docgalina@mail.ru
канд. мед. наук, ассистент каф. онкологии 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
V A Gorbunova
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: veragorbounova@mail.ru
д-р мед. наук, проф., вед. науч. сотр. отд-ния химиотерапии НИИ клинической онкологии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
N F Orel
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: orel.nad@yandex.ru
д-р мед. наук, вед. науч. сотр. отд-ния химиотерапии НИИ клинической онкологии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
N I Perevodchikova
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: n.perevodchikova@mail.ru
д-р мед. наук, проф., вед. науч. сотр. отд-ния химиотерапии НИИ клинической онкологии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
V Yu Bokhyan
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: b.vagan@mail.ru
канд. мед. наук, ст. науч. сотр. отд-ния хирургического №6 абдоминальной онкологии НИИ клинической онкологии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
A A Fedenko
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: fedenko@eesg.ru
д-р мед. наук, зав. отд-нием химиотерапии НИИ клинической онкологии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
References
- Kerkhofs T.M, Verhoeven R.H, Van der Zwan J.M. et al. Adrenocortical carcinoma: A population-based study on incidence and survival in the Netherlands since 1993. EurJ Cancer 2013: epub April, 9th 2013.
- Kebebew E, Reiff E. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 2006;30 (5): 872-8.
- Lucas A, McDuffie L.A. et al. Adrenocortical carcinoma: modern management and evolving treatment strategies. Int J Endocr Oncol 2016; 3 (2): 161-74
- Hescot S, Slama A, Lombes A. et al. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome C oxidase defect in human adrenocortical cells. EndocrRelat Cancer 2013; 20 (3): 371-81.
- Poli G, Guasti D, Rapizzi E. et al. Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocr Relat Cancer2013; 20 (4): 537-50.
- Chortis V, Taylor A.E, Schneider P. et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5alpha-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab 2013; 98 (1): 161-71. 7- Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as et chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol 2009; 274619-29.
- NCCN Clinical practice guidelines in oncology. Neuroendocrine tumors. Version 2.2017: National Comprehensive Cancer Network, 2017.
- Дедов И.И., Мельниченко Г.А, Бельцевич Д.Т. Опыт применения митотана в комплексном лечении адренокортикального рака. Рос. онкол. журн. 2016; 21 (6): 284-92.
- Коломейцева А.А, Горбунова В.А, Переводчикова Н.И. Современное состояние проблемы лечения адренокортикального рака. Современное состояние проблемы лечения адренокортикальногорака. Рос. онкол. журн. 2014; 19 (6): 44-8.
- Berruti A, Terzolo M, Sperone P. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial Endocr Relat Cancer 2005; 12 (3): 657-66.
- Fassnacht M, Terzolo M, Attolio B, FIRM-ACT Study Group et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366 (23): 2189-97.